Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Meniere Disease Overview 6 Therapeutics Development 7 Pipeline Products for Meniere Disease - Overview 7 Meniere Disease - Therapeutics under Development by Companies 8 Meniere Disease - Pipeline Products Glance 9 Late Stage Products 9 Clinical Stage Products 10 Early Stage Products 11 Unknown Stage Products 12 Meniere Disease - Products under Development by Companies 13 Meniere Disease - Companies Involved in Therapeutics Development 14 Orbis Biosciences Inc 14 Otonomy, Inc. 15 Quark Pharmaceuticals, Inc. 16 Sound Pharmaceuticals, Inc. 17 Synphora AB 18 Meniere Disease - Therapeutics Assessment 19 Assessment by Monotherapy Products 19 Assessment by Target 20 Assessment by Mechanism of Action 22 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Drug Profiles 28 betamethasone valerate ER - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 dexamethasone acetate SR - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 latanoprost - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 OR-105 - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 QPHL-2 - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 SPI-1005 - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 Meniere Disease - Dormant Projects 38 Meniere Disease - Product Development Milestones 39 Featured News & Press Releases 39 Aug 01, 2016: Otonomy Successfully Completes One-Year, Multiple-Dose Clinical Safety Trial for OTO-104 in Meniere Disease Patients 39 Mar 23, 2016: Otonomy Initiates Patient Enrollment in Second Phase 3 Clinical Trial of OTO-104 in Ménière’s Disease 39 Jan 26, 2016: Otonomy Announces Publication Supporting Development of OTO-104 as Protectant Against Cisplatin-Induced Hearing Loss 40 Nov 18, 2015: Otonomy Initiates Patient Enrollment in U.S. Phase 3 Clinical Trial of OTO-104 in Meniere Disease 40 Sep 24, 2015: Otonomy to Present Results for OTO-104 Phase 2b Clinical Trials at 2015 AAO-HNSF Annual Meeting 41 Sep 09, 2015: Otonomy Announces Successful End-of-Phase 2 Meeting With the FDA for OTO-104 in Meniere Disease 41 May 21, 2015: Otonomy Reports Phase 2b Topline Data for OTO-104 in Meniere Disease 41 Apr 20, 2015: Otonomy Completes Enrollment of OTO-104 Multiple-Dose Safety Study in Meniere Disease Patients 42 Dec 01, 2014: Otonomy Achieves Patient Enrollment Target in Phase 2b Clinical Trial of OTO-104 in Meniere Disease 43 Oct 09, 2014: Otonomy Enrolls First Meniere Disease Patients in OTO-104 Multiple-Dose Safety Study 43 Dec 11, 2013: Otonomy Enrolls First Patient in Pivotal Phase 2b Study of OTO-104 in Meniere Disease 43 Sep 29, 2011: Otonomy Presents Positive New Findings From Phase Ib Study Of OTO-104 In Meniere Disease At International Conference 44 Apr 28, 2011: Otonomy Announces Positive Results From Phase Ib Study Of OTO-104 In Ménière’s Disease 45 Appendix 47 Methodology 47 Coverage 47 Secondary Research 47 Primary Research 47 Expert Panel Validation 47 Contact Us 47 Disclaimer 48

List of Tables Number of Products under Development for Meniere Disease, H2 2016 7 Number of Products under Development by Companies, H2 2016 8 Comparative Analysis by Late Stage Development, H2 2016 9 Comparative Analysis by Clinical Stage Development, H2 2016 10 Comparative Analysis by Early Stage Development, H2 2016 11 Comparative Analysis by Unknown Stage Development, H2 2016 12 Products under Development by Companies, H2 2016 13 Meniere Disease - Pipeline by Orbis Biosciences Inc, H2 2016 14 Meniere Disease - Pipeline by Otonomy, Inc., H2 2016 15 Meniere Disease - Pipeline by Quark Pharmaceuticals, Inc., H2 2016 16 Meniere Disease - Pipeline by Sound Pharmaceuticals, Inc., H2 2016 17 Meniere Disease - Pipeline by Synphora AB, H2 2016 18 Assessment by Monotherapy Products, H2 2016 19 Number of Products by Stage and Target, H2 2016 21 Number of Products by Stage and Mechanism of Action, H2 2016 23 Number of Products by Stage and Route of Administration, H2 2016 25 Number of Products by Stage and Molecule Type, H2 2016 27 Meniere Disease - Dormant Projects, H2 2016 38 List of Figures Number of Products under Development for Meniere Disease, H2 2016 7 Number of Products under Development by Companies, H2 2016 8 Assessment by Monotherapy Products, H2 2016 19 Number of Products by Targets, H2 2016 20 Number of Products by Stage and Targets, H2 2016 20 Number of Products by Mechanism of Actions, H2 2016 22 Number of Products by Stage and Mechanism of Actions, H2 2016 22 Number of Products by Routes of Administration, H2 2016 24 Number of Products by Stage and Routes of Administration, H2 2016 24 Number of Products by Molecule Types, H2 2016 26 Number of Products by Stage and Molecule Types, H2 2016 26

Orbis Biosciences Inc Otonomy, Inc. Quark Pharmaceuticals, Inc. Sound Pharmaceuticals, Inc. Synphora AB